Retatrutide Beats Ozempic in First Head-to-Head Trial
Lilly's triple agonist faced the highest approved dose of Ozempic head-on in phase 3 — A1C down 2.2 points and weight down 20.9%, more than double Ozempic's loss.
GLP-1s Help Shed Regained Weight After Bariatric Surgery
Patients who regained weight after bariatric surgery lost 14.8% of it on GLP-1 therapy at 12 months vs 8.1% without — with no added complication signal.
GLP-1s vs Other Diabetes Drugs Across 181 Outcomes
A 70,982-patient target trial emulation across 181 outcomes found lower heart and kidney risk on GLP-1s — and higher osteoarthritis and fracture associations to weigh.
EloraTZP Beats Tirzepatide: 23.3% Weight Loss
Lilly paired tirzepatide with eloralintide, an amylin agonist — and the combination left tirzepatide alone far behind on weight and blood sugar.
TikTok Kills Peptide Sales
The hashtags are banned, peptide searches return zero results, and the shops are gone. TikTok's two-year enforcement shift — and what it does to availability.
Foundayo: The Once-Daily GLP-1 Pill
Lilly's first non-peptide oral GLP-1 — no food or water restrictions, no needle, no fridge. New ACHIEVE data shows cardio protection plus 12.4% loss.
Retatrutide's TRIUMPH-2: Triple Agonist Hits 18.8% Weight Loss
Phase 3 results in type 2 diabetes: Lilly's triple-agonist delivered surgical-level weight loss, 1.6-point A1C drops, and FDA filing planned for early 2027.
GLP-1s Reverse Biological Age — By Years
The Longevity Report: GLP-1 therapies are measurably reversing markers of biological aging — in study after study, by years.